4-(16-1H-tetrazol-5-yl-hexadecanoylsulfamoyl)-butyric acid | 873874-16-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-(16-1H-tetrazol-5-yl-hexadecanoylsulfamoyl)-butyric acid
• 英文别名: 4-{[16-(2H-Tetrazol-5-yl)hexadecanoyl]sulfamoyl}butanoic acid；4-[16-(2H-tetrazol-5-yl)hexadecanoylsulfamoyl]butanoic acid
• CAS: 873874-16-9
• 化学式: C₂₁H₃₉N₅O₅S
• 分子量: 473.637
• InChiKey: VSRXCXMAKRXNAO-UHFFFAOYSA-N

物化性质

• 密度：
  1.187±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  32
• 可旋转键数：
  21
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  163
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-(16-1H-tetrazol-5-yl-hexadecanoylsulfamoyl)-butyric acid 、 O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以91%的产率得到4-(16-(tetrazol-5-yl)hexadecanoylsulfamoyl)butyric acid succinimidyl ester
  参考文献：
  名称：

  Protease stabilized acylated insulin analogues

  摘要：

  新型酰化胰岛素类似物具有对蛋白酶的抗性，可以通过肺部或口服有效地给药。这些胰岛素类似物包含B25H和A14E或A14H。

  公开号：

  US09688737B2
• 作为产物：
  描述：

  4-(N-(16-(5-tetrazolyl)hexadecanoyl)sulfamoyl)butyric acid methyl ester 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 19.75h， 以54%的产率得到4-(16-1H-tetrazol-5-yl-hexadecanoylsulfamoyl)-butyric acid
  参考文献：
  名称：

  WO2008/87190

  摘要：

  公开号：

文献信息

• FGF21 derivatives with albumin binder A-B-C-D-E- and their use
  申请人：Tagmose Tina Møller

  公开号：US09480753B2

  公开（公告）日：2016-11-01

  The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.

  本发明涉及成纤维细胞生长因子21（FGF21），更具体地涉及具有结合白蛋白的A-B-C-D-E-共价附加物的FGF21化合物衍生物。本发明还涉及新颖的FGF21类似物，以及这些FGF21衍生物和类似物的药用，特别用于治疗糖尿病、血脂异常、肥胖、心血管疾病、代谢综合征和/或非酒精性脂肪肝病（NAFLD）。本发明的衍生物是持久的，例如能够在较长时间内保持低血糖水平，能够增加FGF21的体内半衰期，并/或导致FGF21的清除率降低。本发明的衍生物最好还具有改善的氧化稳定性。
• [EN] EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS<br/>[FR] ANALOGUES D'EGF(A) AVEC SUBSTITUANTS ACIDES GRAS
  申请人：NOVO NORDISK AS

  公开号：WO2017121850A1

  公开（公告）日：2017-07-20

  The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293- 332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.

  该发明涉及从LDL-R的EGF(A)结构域衍生的化合物，特别是包括野生型EGF(A)(LDL-R(293-332))序列的肽类类似物和至少一个含有至少一个脂肪酸基团的取代基的化合物。该发明还涉及其制药组合物和药物的使用。该发明的新型EGF(A)化合物可用于治疗，例如在降低胆固醇、脂质代谢异常和心血管疾病领域。
• Growth Hormones with Prolonged In-Vivo Efficacy
  申请人：Novo Nordisk HealthCare AG

  公开号：US20180221501A1

  公开（公告）日：2018-08-09

  The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

  本发明涉及优化了亚皮下注射的多肽化合物，例如具有连接剂的生长激素偶联物，该连接剂提供与白蛋白的非共价结合。
• Peptides for Use in the Treatment of Obesity
  申请人：Sensfuss Ulrich

  公开号：US20100016238A1

  公开（公告）日：2010-01-21

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其在调节一种或多种黑素皮质素受体类型方面具有有效性，以及该化合物在治疗中的使用，包括将该化合物用于需要该化合物的患者的治疗方法，以及将该化合物用于制造药物。该发明的化合物在与肥胖相关的多种疾病或病况的治疗方面具有特别的兴趣。
• Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
  申请人：Wulff Birgitte Schjellerup

  公开号：US20100022446A1

  公开（公告）日：2010-01-28

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其能有效调节一个或多个黑色素皮质素受体类型，并且涉及使用这些化合物进行治疗的方法，包括将这些化合物用于需要治疗的患者的治疗方法以及将这些化合物用于制造药物。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面具有特别的兴趣。